- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Intellia Therapeutics Reports Inducement Grants
Biopharmaceutical company awards stock units to new employees under Nasdaq listing rule
Apr. 6, 2026 at 1:55am
Got story updates? Submit your updates here. ›
Intellia Therapeutics, a leading biopharmaceutical company focused on CRISPR gene editing, announced that it awarded inducement grants of time-based restricted stock units (RSUs) for an aggregate of 67,150 shares of the company's common stock to 13 new employees. The grants were made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Why it matters
Intellia's inducement grants to new hires demonstrate the company's continued growth and investment in talent as it works to advance its CRISPR-based therapies. The grants align new employees' interests with those of Intellia and its shareholders through equity compensation.
The details
The RSUs will vest annually over three years, subject to each employee's continued service. The awards were granted outside of Intellia's stockholder-approved equity incentive plans, under the company's 2024 Inducement Plan, which was adopted by the board of directors in June 2024.
- Intellia announced the inducement grants on April 3, 2026.
- The grants were made on April 1, 2026.
The players
Intellia Therapeutics, Inc.
A leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies.
Jason Fredette
Vice President of Investor Relations and Corporate Communications at Intellia Therapeutics.
What they’re saying
“Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies.”
— Intellia Therapeutics
The takeaway
Intellia's inducement grants demonstrate the company's continued growth and investment in talent as it works to advance its CRISPR-based therapies. The equity compensation aligns new employees' interests with those of Intellia and its shareholders.
